John Muir Clinical Lab Offers Affirm VPIII

John Muir Clinical Lab Offers Affirm VPIII

The clinical laboratory at John Muir Medical Center will be offering the Affirmâ„¢ VPIII test for Bacterial Vaginosis/Vaginitis in October of 2006. The Affirm VPIII test is a molecular probe-based system for the rapid diagnosis of the most common causative agents of bacterial vaginosis (BV) and vaginitis; Gardnerella vaginalis; Candida species; Trichomonas vaginalis.

The Affirm VPIII Microbial Identification Test is based on the principles of nucleic acid hybridization. The test uses two distinct single-stranded nucleic acid probes for each organism, a capture probe and a color development probe, that are complementary to unique genetic sequences of the target organisms. Collection: Collect a vaginal specimen using the swab in the ATTS (Ambient Temperature Transport System) set. Label tube with patient name and DOB. In extensive clinical trials, the overall accuracy of Affirm VPIII compared to standard clinical laboratory methods was: 95.8% for Trichomonas (compared to culture and wet mount); 90.2% for Candida (compared to clinically significant culture levels); 97.5% for Gardnerella (compared to Gram stain scored for BV). Use of the Affirm VPIII alleviates the need for examination of the wet mount within 1 hour and reduces the turnaround time for routine genital culture for Gardnerella and Candida species from three days to one.